Skip to main navigation
Logo

Live - Corprorate Menu

  • About Us
    • Our Leadership
    • Collaborations
    • Compliance and Ethics
    • Corporate Giving
  • Our Focus
    • Cerebral Adrenoleukodystrophy
    • Multiple Myeloma
    • Sickle Cell Disease
    • Transfusion Dependant Beta-Thalassemia
  • Our Science
    • What is Gene Therapy?
    • Gene Therapy Techniques
    • Clinical Trials
    • Our Pipeline
  • Patients & Advocacy
    • Patient Advocacy
    • Patient Resources
    • Access Policy

Live - Top Nav

  • investors & media
  • contact us
  • careers
  • stories

Investors & Media

Overview Corporate Governance Press Releases Events & Presentations Analyst Coverage Stock Information SEC Filings Investor FAQs

Toolkit

  • Annual Meeting
  • Information Request
  • Sign Up for Email Alerts
  • RSS Feeds

Media Contacts

  • Sarah Alspach

    Chief Communications Officer

    (857) 299-6198

    sarah.alspach@bluebirdbio.com

  • Jess Rowlands

    Senior Director, Product Communications

    (857) 299-6103

    jess.rowlands@bluebirdbio.com

Investor Contacts

  • Courtney O’Leary

    Investor Relations

    (978) 621-7347

    coleary@bluebirdbio.com

bluebird bio Completes Planned Business Separation

  • Read more about bluebird bio Completes Planned Business Separation

Najoh Tita-Reid

  • Member of the Compensation Committee
  • Member of the Nominating and Corporate Governance Committee
Najoh Tita-Reid
Director

Andrew Obenshain

    Andrew Obenshain
    Director

    Nick Leschly

      Nick Leschly
      Director

      Lis Leiderman

      • Chair of the Audit Committee
      • Member of the Compensation Committee
      Lis Leiderman
      Director
      Financial Expert

      bluebird bio Sets Record Date and Distribution Date for Planned Business Separation

      • Read more about bluebird bio Sets Record Date and Distribution Date for Planned Business Separation

      bluebird bio Provides Update on Upcoming Planned Business Separation

      • Read more about bluebird bio Provides Update on Upcoming Planned Business Separation

      bluebird bio Submits Biologics License Application (BLA) to FDA for betibeglogene autotemcel (beti-cel) Gene Therapy for Patients With β-thalassemia Who Require Regular Red Blood Cell Transfusions

      • Read more about bluebird bio Submits Biologics License Application (BLA) to FDA for betibeglogene autotemcel (beti-cel) Gene Therapy for Patients With β-thalassemia Who Require Regular Red Blood Cell Transfusions

      2seventy bio Announces Upcoming Investor Events

      • Read more about 2seventy bio Announces Upcoming Investor Events

      bluebird bio Secures $75 Million in Private Placement Equity Financing

      • Read more about bluebird bio Secures $75 Million in Private Placement Equity Financing

      Pagination

      • First page « First
      • Previous page ‹ Previous
      • Page 1
      • Page 2
      • Current page 3
      • Page 4
      • Page 5
      • Page 6
      • Page 7
      • Page 8
      • Page 9
      • …
      • Next page Next ›
      • Last page Last »
      Subscribe to

      Quick Links

      • Patients & Advocacy
      • Investors & Media
      • Careers
      • Contact Us

      CONTACT INFO

      info@bluebirdbio.com

      clinicaltrials@bluebirdbio.com

      investor@bluebirdbio.com

      medinfo@bluebirdbio.com

      Live - Terms & Privacy

      • Terms of Service
      • Privacy Policy
      • Cookie Notice
      • Sitemap
      © 2022 bluebird bio, Inc. All Rights Reserved. Corp-GBL-00011 05/19

      Live - Social Links